The list price for Qalsody, the first and only approved treatment to target a genetic cause of ALS, Ionis said,1 may prove controversial. “Biogen anticipates there may be variation in time to treatment as institutions and treatment centers learn about Qalsody,” he noted. The observed reduction in NfL was consistent across all subgroups based on sex, disease duration since symptom onset, site of onset, and use of other medications for ALS treatment. FDA approves QALSODY (tofersen) as the first treatment targeting a genetic cause of ALS. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene.

Source: New York Times April 28, 2023 23:30 UTC